What Zendal does

Zendal Group (legal entity Zendal Health S.A.) is a privately held Spanish biopharmaceutical group headquartered in O Porriño, Pontevedra, operating five GMP-certified production plants across Spain and Portugal and distributing to more than 65 countries. The group is organized as a platform-plus-subsidiary architecture: CZ Vaccines (parent and CDMO franchise), Biofabri (human vaccines, including the Phase 3 MTBVAC tuberculosis candidate), Vetia and Petia (livestock and companion animal health in Spain), Zinereo (pharmaceuticals and probiotics with 80+ years of medicine manufacturing heritage), Probisearch (probiotic R&D services), and the recently integrated Laboratorios Ovejero and Laboratorios Maymó (acquired March 2023). As of 2026 the group employed more than 650 professional staff, reinvests 11%+ of revenue in R&D, and traces its biopharmaceutical track record over 30 years to the 1993 founding of CZ Vaccines within the original Laboratorios Zeltia cluster.

The group's core technology spans proprietary vaccine platforms — Neoleish, the first recombinant DNA vaccine for canine leishmaniasis with over 90% demonstrated effectiveness (launched March 2024); MTBVAC, a live attenuated tuberculosis vaccine in Phase 3 development through Biofabri; and inactivated livestock vaccines including the Bluevac bluetongue range, Colidex for swine colibacilosis, Gudair, the EHD vaccine (EMA-recommended March 2025), and a first trivalent bluetongue vaccine for sheep (European approval April 2026). Revenue is generated through three streams: direct sales of proprietary vaccines and biologics to governments, multinationals, and laboratories via CZ Vaccines, Vetia, and Petia; EU GMP-certified CDMO services for third-party developers from clinical phase I-III through commercial manufacturing; and pharmaceutical and probiotic product sales through the Zinereo and Probisearch brands. Go-to-market is sales-led through direct subsidiaries and government/multi-national tenders, with international distribution via own subsidiaries and partner distributors. Strategic positioning is anchored on the One Health framework (joining the One Health Platform in 2021), and the group was appointed by the EU in 2023 alongside Reig Jofre to guarantee European vaccine production capacity for future health emergencies.

Name

Zendal

Legal name

Zendal Health S.A.

Website

https://zendal.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Zendal is a privately held Spanish biopharmaceutical group operating five GMP-certified production plants in Spain and Portugal. It develops, manufactures, and commercializes vaccines, biologicals, probiotics, and pharmaceutical products across human and animal health, serving governments, multinationals, and laboratories in 65+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Pontevedra

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Vaccine and Biological Product Manufacturing: Research, development, manufacturing and commercialization of biologics, vaccines, pharmaceuticals and probiotics for human and animal health. CZ Vaccines serves as the main European actor in biotechnological development and manufacturing, producing for laboratories, multinationals and governments globally.
2. CDMO Services: Contract Development and Manufacturing Organization services offered to third-party companies with EU GMP certification, providing development through clinical phase I-III and commercial manufacturing capabilities
3. Pharmaceutical Products: Production and sale of pharmaceutical medicines and probiotics of pharmaceutical quality through Zinereo brand, with over 80 years of experience in development and manufacture of medicines

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Zendal is a vertically integrated biopharmaceutical group that researches, develops, manufactures, and commercializes vaccines, biological products, probiotics, and pharmaceutical products for human and animal healthcare. Its portfolio spans proprietary vaccines (Neoleish, MTBVAC, Bluevac, Colidex, EHD, trivalent bluetongue) plus CDMO services offered through EU GMP-certified facilities to third-party laboratories, multinationals, and governments across 65+ countries.

Product overview

Zendal Group is a biopharmaceutical conglomerate operating a platform-plus-subsidiary architecture, comprising eight companies focused on research, development, manufacturing, and marketing of biologicals, vaccines, probiotics, and pharmaceutical products for human and animal healthcare. The portfolio is organized across specialized subsidiaries: CZ Vaccines serves as the parent company and primary CDMO services provider with EU GMP certification; Biofabri handles human vaccines including the Phase 3 MTBVAC tuberculosis vaccine; Vetia and Petia address livestock and companion animal health respectively; Zinereo and Probisearch focus on probiotics; Laboratorios Ovejero and Maymó (acquired 2023) round out the group. Key products include Neoleish (first recombinant DNA vaccine for canine leishmaniasis), Bluevac and Gudair (livestock vaccines), trivalent bluetongue vaccine, and the EHD vaccine. The group operates five production plants across Spain and Portugal, maintains R&D centers in multiple locations, and distributes to over 65 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Neoleish: First recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness against canine leishmaniasis.
• MTBVAC
• Bluevac
• Gudair
• Colidex
• Llovet

Products and services

• Neoleish Recombinant DNA Vaccine First recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness. Developed in partnership with the Spanish National Research Council (CSIC). Targets canine leishmaniasis prevention in companion animals (dogs), distributed to veterinary professionals.
• Bluevac Bluetongue Vaccine Range of inactivated vaccines to combat bluetongue disease in bovine cattle and sheep. Part of Vetia's livestock vaccine portfolio distributed in Europe.
• Trivalent Bluetongue Vaccine (serotypes 1, 4 and 8) First trivalent bluetongue vaccine for sheep covering serotypes 1, 4 and 8. Received European approval in April 2026. Target segment: ovine livestock.
• Epizootic Haemorrhagic Disease (EHD) Vaccine First vaccine against Epizootic Haemorrhagic Disease (EHD) launched in Spain. EMA recommendation received March 2025. Used for livestock disease prevention.
• Gudair Vaccine Vaccine product in the Zendal animal health portfolio, listed as a distinctive offering alongside Bluevac and Neoleish. Used for livestock disease prevention.
• Colidex Swine Colibacilosis Vaccine Vaccine against swine colibacilosis, part of Vetia's range of biological products for swine animals. Targets livestock producers and the swine farming industry.
• CDMO Services (Contract Development and Manufacturing) Contract Development and Manufacturing Organization services offered to third-party companies with EU GMP certification, providing development through clinical phase I-III and commercial manufacturing capabilities. CZ Vaccines serves as the main European CDMO actor in biotechnological development and manufacturing, producing for laboratories, multinationals and governments globally.

Quantifiable outcome

• Neoleish vaccine demonstrated over 90% effectiveness against canine leishmaniasis
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• IMAGINE Clinical Trial PartnerscoreStrategic or Co-development Partner · 1 February 2025Biofabri and IAVI announced first vaccinations in IMAGINE clinical trial - a large-scale safety and efficacy trial of tuberculosis vaccine candidate MTBVAC.
• TBVIcoreStrategic or Co-development Partner · 1 June 2024TBVI (TuBercculosis Vaccine Initiative) signed contract with European Health and Digital Executive Agency to accelerate final development of MTBVAC tuberculosis vaccine candidate.
• Spanish National Research Council (CSIC)coreStrategic or Co-development Partner · 1 March 2024Partnership for development of Neoleish recombinant DNA vaccine - the first recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness. CSIC collaboration provided the scientific foundation for this innovative vaccine technology.
• Reig JofrecoreStrategic or Co-development Partner · 1 July 2023Joint appointment by EU to ensure vaccine production capacity in Europe in case of future health emergencies, combining Zendal's manufacturing expertise with Reig Jofre's capabilities.
• Bharat BiotechcoreStrategic or Co-development Partner · 1 March 2022Partnership for development, manufacturing and distribution of MTBVAC novel tuberculosis vaccine. BIOFABRI and Bharat Biotech partnered to make the TB vaccine available globally.
• IAVIcoreStrategic or Co-development Partner · 1 July 2021Partnership to advance tuberculosis vaccine candidate MTBVAC into efficacy trials. IAVI and Zendal announced expanded agreement in 2023 to partner on development of MTBVAC, with IAVI receiving funding for efficacy trial in Africa.
• One Health PlatformminorOthers · 1 January 2021Joined the One Health Platform at end of 2021 - a network at state level combining efforts of over 100 organisations with interdisciplinary and cross-sectional nature promoting integrated health approaches.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Valneva: European specialty vaccine company combining proprietary vaccine development with CDMO services. Mirrors Zendal's hybrid proprietary-vaccine + biologics-CDMO model and shares a similar scale and European footprint.
• Bavarian Nordic: Specialty vaccine developer and CDMO with proprietary late-stage vaccine assets. Comparable to Zendal on the biologics-CDMO plus proprietary-vaccine business mix (Biofabri/CZ Vaccines) and clinical-stage execution model.
• Bharat Biotech: Indian vaccine developer partnered with Zendal/BioFabri on MTBVAC. Comparable across innovative human-vaccine development, recombinant platforms, and global distribution via licensing partnerships.
• HIPRA: Spanish animal-health and human-vaccine manufacturer headquartered in Girona. Directly comparable to Zendal's Vetia, Petia, and Biofabri businesses across livestock, companion-animal, and human vaccines within the same Iberian ecosystem.
• IDT Biologika: German CDMO focused on vaccines and biologics with EU GMP manufacturing capacity. Directly comparable to CZ Vaccines' biologics-CDMO proposition and EU strategic-manufacturing positioning.

Broad incumbents

• Sanofi Pasteur: Sanofi's vaccine franchise, one of the world's largest human-vaccine manufacturers. Provides a benchmark for Biofabri's MTBVAC aspirations in terms of scale, regulatory muscle, and global public-health tenders.
• Merck Animal Health (MSD AH): Animal-health division of Merck/MSD with a global livestock and companion-animal vaccine franchise. Comparable at the portfolio level to Zendal's Vetia, especially in ruminant and swine vaccine categories.
• Zoetis: Largest global animal-health company with a comprehensive vaccine portfolio for livestock and companion animals. Provides the upper-end scale benchmark for Zendal's Vetia and Petia franchises.
• GSK Vaccines: Global vaccine leader across pediatric, travel, and endemic-disease segments. Comparable to Zendal's biologics manufacturing and CDMO ambitions, particularly in mass-vaccination public-health contracts.
• Boehringer Ingelheim Animal Health: Animal-health division of Boehringer Ingelheim covering livestock and companion-animal vaccines and pharmaceuticals. Broad incumbent whose veterinary vaccine portfolio overlaps with Zendal's Vetia products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/zendalgroup
• YouTubeyoutube.com/channel/UCW4Vo6yzb0RWSxctHWYvX1A
• LinkedInin.linkedin.com/company/zendal

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zendal